Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 14, 2023; 29(10): 1614-1626
Published online Mar 14, 2023. doi: 10.3748/wjg.v29.i10.1614
Published online Mar 14, 2023. doi: 10.3748/wjg.v29.i10.1614
Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
Yan-Yu Wang, Xu Yang, Yun-Chao Wang, Jun-Yu Long, Hui-Shan Sun, Yi-Ran Li, Zi-Yu Xun, Nan Zhang, Cong Ning, Jun-Wei Zhang, Cheng-Pei Zhu, Xiao-Bo Yang, Hai-Tao Zhao, Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
Jing-Nan Xue, Long-Hao Zhang, Department of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou Province, China
Author contributions: Wang YY participated in the study design and drafting of the manuscript; Yang X, Wang YC, Long JY, Sun HS, Li YR, Xun ZY, Zhang N, Xue JN and Ning C participated in data collection and statistical analysis; Zhang JW, Zhu CP, Yang XB, and Zhao HT participated in study supervision; and all authors have read and approved the final manuscript.
Supported by Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences , No. 2021-I2M-1-061 and 2021-I2M-1-003 ; Chinese Society of Clinical Oncology-Hengrui Cancer Research Fund , No. Y-HR2019-0239 ; Chinese Society of Clinical Oncology-MSD Cancer Research Fund , No. Y-MSDZD2021-0213 ; and National Ten-thousand Talent Program.
Institutional review board statement: This study was approved by the Ethical Review Board at Peking Union Medical College Hospital (No.SK-2000).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Tao Zhao, MD, PhD, Professor, Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1, Shuaifuyuan, Dongcheng District, Beijing 100730, China. zhaoht@pumch.cn
Received: November 30, 2022
Peer-review started: November 30, 2022
First decision: December 20, 2022
Revised: December 24, 2022
Accepted: February 27, 2023
Article in press: February 27, 2023
Published online: March 14, 2023
Processing time: 99 Days and 21.1 Hours
Peer-review started: November 30, 2022
First decision: December 20, 2022
Revised: December 24, 2022
Accepted: February 27, 2023
Article in press: February 27, 2023
Published online: March 14, 2023
Processing time: 99 Days and 21.1 Hours
Core Tip
Core Tip: This retrospective research was designed to evaluate the treatment outcome and safety of transarterial chemoembolization (TACE) and lenvatinib plus programmed death receptor-1 (PD-1) inhibitors in the treatment of patients with unresectable hepatocellular carcinoma (uHCC). Patients with uHCC who underwent PD-1 inhibitors, lenvatinib, TACE therapy (n = 45) had a evidently longer overall survival than those who underrwent lenvatinib, TACE therapy (n = 20, 26.8 vs 14.0 mo; P = 0.027). Early combination of PD-1 inhibitors has manageable toxicity and hopeful efficacy in patients with uHCC.